Dengue infection in children in Ratchaburi, Thailand: a cohort study. I. Epidemiology of symptomatic acute dengue infection in children, 2006-2009

PLoS Negl Trop Dis. 2012;6(7):e1732. doi: 10.1371/journal.pntd.0001732. Epub 2012 Jul 31.

Abstract

Background: There is an urgent need to field test dengue vaccines to determine their role in the control of the disease. Our aims were to study dengue epidemiology and prepare the site for a dengue vaccine efficacy trial.

Methods and findings: We performed a prospective cohort study of children in primary schools in central Thailand from 2006 through 2009. We assessed the epidemiology of dengue by active fever surveillance for acute febrile illness as detected by school absenteeism and telephone contact of parents, and dengue diagnostic testing. Dengue accounted for 394 (6.74%) of the 5,842 febrile cases identified in 2882, 3104, 2717 and 2312 student person-years over the four years, respectively. Dengue incidence was 1.77% in 2006, 3.58% in 2007, 5.74% in 2008 and 3.29% in 2009. Mean dengue incidence over the 4 years was 3.6%. Dengue virus (DENV) types were determined in 333 (84.5%) of positive specimens; DENV serotype 1 (DENV-1) was the most common (43%), followed by DENV-2 (29%), DENV-3 (20%) and DENV-4 (8%). Disease severity ranged from dengue hemorrhagic fever (DHF) in 42 (10.5%) cases, dengue fever (DF) in 142 (35.5%) cases and undifferentiated fever (UF) in 210 (52.5%) cases. All four DENV serotypes were involved in all disease severity. A majority of cases had secondary DENV infection, 95% in DHF, 88.7% in DF and 81.9% in UF. Two DHF (0.5%) cases had primary DENV-3 infection.

Conclusion: The results illustrate the high incidence of dengue with all four DENV serotypes in primary school children, with approximately 50% of disease manifesting as mild clinical symptoms of UF, not meeting the 1997 WHO criteria for dengue. Severe disease (DHF) occurred in one tenth of cases. Data of this type are required for clinical trials to evaluate the efficacy of dengue vaccines in large scale clinical trials.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antibodies, Viral / blood
  • Child
  • Child, Preschool
  • Cohort Studies
  • Dengue / epidemiology*
  • Dengue / pathology*
  • Dengue Virus / isolation & purification*
  • Female
  • Humans
  • Immunoenzyme Techniques
  • Immunoglobulin G / blood
  • Immunoglobulin M / blood
  • Incidence
  • Male
  • Prospective Studies
  • RNA, Viral / blood
  • Reverse Transcriptase Polymerase Chain Reaction
  • Severity of Illness Index
  • Thailand / epidemiology

Substances

  • Antibodies, Viral
  • Immunoglobulin G
  • Immunoglobulin M
  • RNA, Viral

Grants and funding

This work was supported technically and fiscally by the Pediatric Dengue Vaccine Initiative (PDVI) project No. VE-2, with in kind support from Mahidol University Faculty of Tropical Medicine, and with in kind and fiscal support by the Department of Disease Control, Ministry of Public Health, Thailand. The PDVI was a Program of the International Vaccine Institute (IVI), Seoul, Korea, and received the majority of its funding from the Bill and Melinda Gates Foundation (grant number 23197). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.